Hormone therapy in Brazilian postmenopausal women with chronic hepatitis C: a pilot study

References

• Barth H, Liang TJ, Baumert TF. Hepatitis C virus entry: molecular biology and clinical implications. Hepatology 2006;44:527–535
   PubMed Web of Science ®Google Scholar
• Management of Hepatitis C: 2002. NIH Consensus Development Conference Statement, June 10–12, 2002. http://consensus.nih.gov/2002/2002Hepatitisc2002116html.htm
   Google Scholar
• Weissenborn K, Ennen JC, Bokemeyer M, et al Monoaminergic neurotransmission is altered in hepatitis C virus infected patients with chronic fatigue and cognitive impairment. Gut 2006;55:1624–1630
   PubMed Web of Science ®Google Scholar
• Poynard T, Ratziu V, Charlotte F, Goodman Z, McHutchison J, Albrecht J. Rates and risk factors of liver fibrosis progression in patients with chronic hepatitis C. J Hepatol 2001;34:730–739
   PubMed Web of Science ®Google Scholar
• Di Martino V, Lebray P, Myers RP, et al Progression of liver fibrosis in women infected with hepatitis C: long-term benefit of estrogen exposure. Hepatology 2004;40:1426–1433
   PubMed Web of Science ®Google Scholar
• Marinho RM, Soares JM Jr, Santiago RC, et al Effects of estradiol on the cognitive function of postmenopausal women. Maturitas 2008;60:230–234
   PubMed Web of Science ®Google Scholar
• Honjo H, Taketani Y. Low-dose estradiol for climacteric symptoms in Japanese women: a randomized, controlled trial. Climacteric 2009;12:227–236
   Google Scholar
• Galhardo CL, Soares JM Jr, Simões RS, Haidar MA, Rodrigues de Lima G, Baracat EC. Estrogen effects on the vaginal pH, flora and cytology in late postmenopause after a long period without hormone therapy. Clin Exp Obstet Gynecol 2006;33:85–89
   PubMed Web of Science ®Google Scholar
• Reuse C, Fraisse T, Luzuy F, et al Menopause: where are we three years beyond WHI? Rev Med Suisse 2006;2:467–470
   PubMedGoogle Scholar
• Rinaldi M, Cagnacci A, Pansini FE, et al Neutral effect of prolonged transdermal hormone therapy on liver function of postmenopausal women with chronic active hepatitis. Menopause 2005;12:619–622
   PubMed Web of Science ®Google Scholar
• O'Donohue J, Williams R. Hormone replacement therapy in women with liver disease. Br J Obstet Gynaecol 1997;104:1–3
   PubMedGoogle Scholar
• Collier J. Bone disorders in chronic liver disease. Hepatology 2007;46:1271–1278
   PubMed Web of Science ®Google Scholar
• Taner MZ, Ozpolat E, Taskiran C, et al Effects of four different regimes of hormone replacement therapy on hemostatic parameters: a prospective randomized study. Maturitas 2006;53:267–273
   PubMed Web of Science ®Google Scholar
• Scarabin P-Y, Oger E, Plu-Bureau G; EStrogen and THromboEmbolism Risk (ESTHER) Study Group. Differential association of oral and transdermal estrogen-replacement therapy with venous thromboembolism risk. Lancet 2003;362:428–432
   PubMed Web of Science ®Google Scholar
• Codes L, Asselah T, Cazals-Hatem D, et al Liver fibrosis in women with chronic hepatitis C: evidence for the negative role of the menopause and steatosis and the potential benefit of hormone replacement therapy. Gut 2007;56:390–395
   PubMed Web of Science ®Google Scholar
• Fardellone P. Predicting the fracture risk in 2008. Joint Bone Spine 2008;75:661–664
   PubMed Web of Science ®Google Scholar
• Kupperman HS, Wetchler BB, Blatt MH. Contemporary therapy of the menopausal syndrome. JAMA 1959;171:1627–1637
   PubMed Web of Science ®Google Scholar
• Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet 1997;349:825–832
   PubMed Web of Science ®Google Scholar
• Dufour R, ed. Laboratory Guidelines for Screening, Diagnosis and Monitoring of Hepatic Injury. Washington: The National Academy of Clinical Biochemistry, 2000; Vol 12
   Google Scholar
• Green D. Disorders of the vitamin K-dependent coagulation factors. In Beutler E, Lichman MA, eds. Hematology, 5th edn. New York: McGraw-Hill, 1995:272–286
   Google Scholar
• Thomas L, Muller M, Schumann, et al Consensus of DGKL and VDGH for interim reference intervals on enzymes in serum. J Lab Med 2005;29:301–308
   Google Scholar
• Thomas L. Clinical and Laboratory Diagnostics, 5th edn. Frankfurt/Main, Germany: TH Books, Verlagsgesellschaft mbH, 1998
   Google Scholar
• Singer JM, Andrade DF. Analysis of longitudinal data. In Sen PK, Rao CR, eds. Handbook of Statistics. Amsterdam: North Holland, 2000:115–160
   Google Scholar
• Neter J, Kutner MH, Nachtsheim CJ, Wasserman W. Applied Linear Statistical Models, 4th edn. Chicago, IL: Irwin/McGraw-Hill, 1996
   Google Scholar
• Scheffé H. A method for judging all contrasts in the analysis of variance. Biometrika 1953;40:87–104
   Web of Science ®Google Scholar
• Pereira SP, O'Donohue J, Moniz C, et al Transdermal hormone replacement therapy improves vertebral bone density in primary biliary cirrhosis: results of a 1 year controlled trial. Aliment Pharmacol Ther 2004;19:563–570
   PubMed Web of Science ®Google Scholar
• Boone RH, Cheung AM, Girlan LM, Heathcote EJ. Osteoporosis in primary biliary cirrhosis: a randomised trial of the efficacy and feasibility of estrogen/progestin. Dig Dis Sci 2006;51:1103–1112
   PubMed Web of Science ®Google Scholar
• Christiansen C, Rodbro P, Tjellesen L. Serum alkaline phosphatase during hormone treatment in postmenopausal women. Acta Med Scand 1984;216:11–17
   PubMed Web of Science ®Google Scholar
• Moore B, Panterson M, Sturdee D. Effect of oral hormone replacement therapy on liver function tests. Maturitas 1987;9:7–15
   PubMed Web of Science ®Google Scholar
• Ormarsdottir S, Mallmin H, Naessen T, et al An open, randomized, controlled study of transdermal hormone replacement therapy on the rate of bone loss in primary biliary cirrhosis. J Intern Med 2004;256:63–69
   PubMed Web of Science ®Google Scholar
• Canonico M, Oger E, Plu-Bureau G, et al for the Estrogen and Thromboembolism Risk (ESTHER) Study. Hormone therapy and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration and progestogens: the ESTHER study. Circulation 2007;115:840–845
   PubMed Web of Science ®Google Scholar
• Brambilla G, Martelli A. Are some progestins genotoxic liver carcinogens? Mutat Res 2002;512:155–163
   PubMed Web of Science ®Google Scholar
• Kuhl H, Wiegratz I. Can 19-nortestosterone derivatives be aromatized in the liver of adult humans? Are there clinical implications? Climacteric 2007;10:344–353
   PubMed Web of Science ®Google Scholar
• Kim WR, Poterucha JJ, Wiesner RH. The relative role of the Child-Pugh classification and the Mayo natural history model in the assessment of survival in patients with primary sclerosing cholangitis. Hepatology 1999;29:1643–1648
   PubMed Web of Science ®Google Scholar
• Shimizu I. Impact of estrogens on the progression of liver disease. Liver Int 2003;23:63–69
   PubMed Web of Science ®Google Scholar
• Zhou Y, Shimizu I, Lu G, et al Hepatic stellate cells contain the functional estrogen receptor β but not the estrogen receptor α in male and female rats. Biochem Biophys Res Commun 2001;286:1059–1065
   PubMed Web of Science ®Google Scholar
• Gressner OA, Weiskirchen R, Gressner AM. Biomarkers of hepatic fibrosis, fibrogenesis and genetic pre-disposition pending between fiction and reality. J Cell Mol Med 2007;11:1031–1051
   PubMed Web of Science ®Google Scholar